Insider · CIK 0001331860
Anthony Gregg Lapointe
director
Files at SNGX (SOLIGENIX, INC.), RIGL (RIGEL PHARMACEUTICALS INC), ATXS (Astria Therapeutics, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +78,947 | $0.00 | $0 | 78,947 | 24 d ago |
| Jun 20, 2025 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +17,647 | $0.00 | $0 | 17,647 | Jun 20, 2025 |
| Jun 11, 2025 | ATXS Astria Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +26,550 | $0.00 | $0 | 26,550 | Jun 12, 2025 |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Common Stock | +2,500 | $0.00 | $0 | 12,500 | May 28, 2025 |
| May 23, 2025 | RIGL RIGEL PHARMACEUTICALS INC | AGrant or award Stock Option (Right to Buy)derivative | +3,000 | $0.00 | $0 | 3,000 | May 28, 2025 |
| Dec 12, 2024 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +8,646 | $0.00 | $0 | 8,646 | Dec 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.